Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis-update of clinical and translational data from the ongoing MANIFEST trial
Curto-Garcia N. et al, (2022), BRITISH JOURNAL OF HAEMATOLOGY, 197, 75 - 76
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk None. and COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium None., (2022), Cell, 185, 916 - 938.e58
A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.
Mead AJ. et al, (2022), Ther Adv Hematol, 13
Defining disease modification in myelofibrosis in the era of targeted therapy
Pemmaraju N. et al, (2022), Cancer
Ezh2 is essential for the generation of functional yolk sac derived erythro-myeloid progenitors.
Neo WH. et al, (2021), Nat Commun, 12
A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program.
Rice S. et al, (2021), Nat Commun, 12
A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis
Gill H. et al, (2021), BLOOD, 138
Single-Cell Multi-Omics Reveals the Genetic, Cellular and Molecular Landscape of TP53 Mutated Leukemic Transformation in MPN
Rodriguez-Meira A. et al, (2021), BLOOD, 138
The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders.
Cross NCP. et al, (2021), Br J Haematol, 195, 338 - 351
CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) PROTEIN INHIBITOR, IN COMBINATION WITH RUXOLITINIB, IN JAK INHIBITOR-NAIVE MYELOFIBROSIS PATIENTS: UPDATE OF MANIFEST PHASE 2 STUDY
Palandri F. et al, (2021), HAEMATOLOGICA, 106, 5 - 6
THE BET INHIBITOR, CPI-0610, PROMOTES MYELOID DIFFERENTIATION IN MYELOFIBROSIS (MF) PATIENT BONE MARROW AND PERIPHERAL CD34+HEMATOPOIETIC STEM CELLS
Vannucchi A. et al, (2021), HAEMATOLOGICA, 106, 51 - 51
Transitions in lineage specification and gene regulatory networks in hematopoietic stem/progenitor cells over human development.
Roy A. et al, (2021), Cell Rep, 36
Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia.
Iskander D. et al, (2021), Sci Transl Med, 13
Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study
Gupta V. et al, (2021), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21, S362 - S362
CPI-0610, a bromodomain and extraterminal domain (BET) protein inhibitor, in combination with ruxolitinib, in JAK-inhibitor-naive myelofibrosis patients: Update of MANIFEST phase 2 study
Platzbecker U. et al, (2021), ONCOLOGY RESEARCH AND TREATMENT, 44, 158 - 158
Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.
Chowdhury O. et al, (2021), Br J Haematol, 194, 1010 - 1015
Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients
Mesa R. et al, (2021), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21, S360 - S360
Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm.
Salisbury RA. et al, (2021), Leukemia, 35, 2424 - 2430